FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206982> ?p ?o ?g. }

• W4387206982 endingPage "e421" @default.
• W4387206982 startingPage "e421" @default.
• W4387206982 abstract "Aiming to determine long-term outcomes post biochemical failure (BF) in patients (pts) treated for intermediate-risk prostate cancer, we analyzed data from our prospective randomized trial (PCS III).From December 2000 to September 2010, 600 pts with intermediate risk prostate cancer (IRPC) received prostate radiotherapy (RT) with or without short-term (6 months) androgen deprivation therapy (ADT) on a Phase III trial. We report death rate from prostate cancer, rate and timing of BF plus the final clinical outcome of patients, alive or dead, with BF. Chi-squared test was used to compare BF and prostate cancer progression (PCP) rates between patient with or without ADT.Median age at randomization was 71 years (IQR 66-74). With a median follow-up (FU) of 13.5 years (IQR 11.2-17.0), 74.5% (447/600) were free from BF at last FU. Of these, 211 died, 79 stopped FU after 10 years, 9 were lost to FU, 6 withdrew from the study and 142 are still on FU, at a median follow-up of 13.2 years (IQR = 10.9 - 16.2). A total of 153 pts (25.5%) developed BF at a median time of 6.5 years post-randomization. Among BF pts, 82/153 died: we documented 32 deaths from prostate cancer (DPC) at a median time of 6 years post-BF and 50/153 pts died from other causes at a median time of 4.7 years from BF. 48/153 BF pts continue on FU: 34 show no clinical evidence of cancer, 9 developed a second cancer and 5 show clinical evidence of PCP. 20/153 pts stopped FU after 10 years: 3 of them with PCP. 3/153 pts were lost to FU: 1 after 3 years with prostate bone metastasis and 2 after 13 years of FU. In the first 5 years post-randomization, 47 pts (7.8%) presented BF with 1 (0.2%) DPC; between 6 and 10 years, there were another 84 (14%) BFs and 11 (1.8%) DPC. Finally, after 10 years and beyond, we recorded an additional 22 (3.7%) BFs and 20 (3.3%) DPC. The rate of patients who received ADT was significantly lower in patients with BF (74/153 = 48.4%) compared to patients without BF (324/447 = 72.5%), p<0.001. The rate of patients who received ADT was also significantly lower in patients with PCP (19/48 = 39.6%) compared to patients without PCP (379/552 = 68.7%), p<0.001.In our trial for intermediate-risk prostate cancer, a quarter of the pts developed BF. Most of the BFs occurred between 5- and 10- year post-randomization. Deaths due to prostate cancer post-BF occurred at a median time of 6 years, justifying the need for long-term FU. BF and PCP were significantly higher in patients not receiving ADT." @default.
• W4387206982 created "2023-09-30" @default.
• W4387206982 creator A5001576092 @default.
• W4387206982 creator A5009524904 @default.
• W4387206982 creator A5019527975 @default.
• W4387206982 creator A5020598292 @default.
• W4387206982 creator A5025499814 @default.
• W4387206982 creator A5027269011 @default.
• W4387206982 creator A5036530578 @default.
• W4387206982 creator A5037727718 @default.
• W4387206982 creator A5042661444 @default.
• W4387206982 creator A5062239241 @default.
• W4387206982 creator A5066542549 @default.
• W4387206982 creator A5079343581 @default.
• W4387206982 date "2023-10-01" @default.
• W4387206982 modified "2023-10-09" @default.
• W4387206982 title "Biochemical Failure in Intermediate Risk Prostate Cancer: Then What? Long-Term Data from a Phase III Trial" @default.
• W4387206982 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1576" @default.
• W4387206982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785385" @default.
• W4387206982 hasPublicationYear "2023" @default.
• W4387206982 type Work @default.
• W4387206982 citedByCount "0" @default.
• W4387206982 crossrefType "journal-article" @default.
• W4387206982 hasAuthorship W4387206982A5001576092 @default.
• W4387206982 hasAuthorship W4387206982A5009524904 @default.
• W4387206982 hasAuthorship W4387206982A5019527975 @default.
• W4387206982 hasAuthorship W4387206982A5020598292 @default.
• W4387206982 hasAuthorship W4387206982A5025499814 @default.
• W4387206982 hasAuthorship W4387206982A5027269011 @default.
• W4387206982 hasAuthorship W4387206982A5036530578 @default.
• W4387206982 hasAuthorship W4387206982A5037727718 @default.
• W4387206982 hasAuthorship W4387206982A5042661444 @default.
• W4387206982 hasAuthorship W4387206982A5062239241 @default.
• W4387206982 hasAuthorship W4387206982A5066542549 @default.
• W4387206982 hasAuthorship W4387206982A5079343581 @default.
• W4387206982 hasConcept C121608353 @default.
• W4387206982 hasConcept C126322002 @default.
• W4387206982 hasConcept C126894567 @default.
• W4387206982 hasConcept C141071460 @default.
• W4387206982 hasConcept C168563851 @default.
• W4387206982 hasConcept C188816634 @default.
• W4387206982 hasConcept C204243189 @default.
• W4387206982 hasConcept C2776235491 @default.
• W4387206982 hasConcept C2777899217 @default.
• W4387206982 hasConcept C2780192828 @default.
• W4387206982 hasConcept C509974204 @default.
• W4387206982 hasConcept C535046627 @default.
• W4387206982 hasConcept C71924100 @default.
• W4387206982 hasConceptScore W4387206982C121608353 @default.
• W4387206982 hasConceptScore W4387206982C126322002 @default.
• W4387206982 hasConceptScore W4387206982C126894567 @default.
• W4387206982 hasConceptScore W4387206982C141071460 @default.
• W4387206982 hasConceptScore W4387206982C168563851 @default.
• W4387206982 hasConceptScore W4387206982C188816634 @default.
• W4387206982 hasConceptScore W4387206982C204243189 @default.
• W4387206982 hasConceptScore W4387206982C2776235491 @default.
• W4387206982 hasConceptScore W4387206982C2777899217 @default.
• W4387206982 hasConceptScore W4387206982C2780192828 @default.
• W4387206982 hasConceptScore W4387206982C509974204 @default.
• W4387206982 hasConceptScore W4387206982C535046627 @default.
• W4387206982 hasConceptScore W4387206982C71924100 @default.
• W4387206982 hasIssue "2" @default.
• W4387206982 hasLocation W43872069821 @default.
• W4387206982 hasLocation W43872069822 @default.
• W4387206982 hasOpenAccess W4387206982 @default.
• W4387206982 hasPrimaryLocation W43872069821 @default.
• W4387206982 hasRelatedWork W1546784169 @default.
• W4387206982 hasRelatedWork W1980245127 @default.
• W4387206982 hasRelatedWork W2030798726 @default.
• W4387206982 hasRelatedWork W2127440557 @default.
• W4387206982 hasRelatedWork W2761687716 @default.
• W4387206982 hasRelatedWork W3021633275 @default.
• W4387206982 hasRelatedWork W4220991042 @default.
• W4387206982 hasRelatedWork W4221041809 @default.
• W4387206982 hasRelatedWork W4319748405 @default.
• W4387206982 hasRelatedWork W95247034 @default.
• W4387206982 hasVolume "117" @default.
• W4387206982 isParatext "false" @default.
• W4387206982 isRetracted "false" @default.
• W4387206982 workType "article" @default.